Figure 5From: Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand Expected value of perfect information. (A) Expected value of perfect population information for a model using the input parameters of general population aged 18 years, and using characteristics of vaccine hypothesis as follows: 31.2% of vaccine efficacy, 210 THB vaccine costs, 80% acceptance rate, 10-year protection, and 3 boosters with full courses. THB: Thai baht as of 2009 value. (B) Partial expected value of perfect information of parameters used in the model at a ceiling ratio of 100,000 THB per QALY gained for the provision of a HIV vaccination program for the general population aged 18 years and using characteristics of vaccine hypothesis as follows: 31.2% vaccine efficacy, 210 THB vaccine costs, 80% acceptance rate, 10-year protection, and 3 boosters with full courses. THB: Thai baht as of 2009 value; QALY: quality adjusted life year; pHIVneg_HIVpos_Base: the probability of HIV infection among the general population; pAsym_Sym: the probability of transition from HIV infection with asymptomatic state to a symptomatic state; pAsym_Death: the probability of transition from HIV infection with asymptomatic state to death; pSym_AIDS: the probability of transition from HIV infection with symptomatic state to AIDS state; HzFnSymp_death: the probability of death from HIV infection with symptomatic state analyzed from parametric survival analysis; HzFnAIDS_death: the probability of death during AIDS state analyzed from parametric survival analysis; HzFnReg1_Reg2: the probability of switching ART first regimens to second regimens among AIDS patients analyzed from parametric survival analysis; HzFnReg2_Reg3: the probability of switching ART second regimens to third regimens among AIDS patients analyzed from parametric survival analysis; C_ComEn: individual cost of community engagement; C_Screen: HIV screening cost; C_PreCou: cost of pre-counseling; TC_Asymp: total treatment cost of HIV infection in asymptomatic state; TC_Sym; total treatment cost of HIV infection in symptomatic state; TC_NewAIDS: total treatment cost of new AIDS patient; TC_AIDS_Reg1: total cost of treatment with the first ART regimens of AIDS patient; TC_AIDS_Reg2: total cost of treatment with the second ART regimens of AIDS patient; TC_AIDS_Reg3: total cost of treatment with the third ART regimens of AIDS patient; TC_AIDS: total cost of other treatment of AIDS patient; Uasym: utility weight of HIV infection with asymptomatic patient; Usym: utility weight of HIV infection with symptomatic patient; UAIDS utility weight of AIDS patient; Risk: percentage of change in the risk behavior post-vaccination; Boost: the duration of vaccine protection; and Vac_eff: vaccine efficacyBack to article page